NCT04826159View on ClinicalTrials.gov

IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

August 6, 2024

Study Completion Date

August 6, 2024

Conditions
Type 2 DiabetesDiabetic CardiomyopathiesHFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

IMB-1018972

Modified release tablet for oral administration

Trial Locations (1)

OX3 9DU

Oxford University Hospital, Oxford

Sponsors
All Listed Sponsors
collaborator

University of Oxford

OTHER

lead

Imbria Pharmaceuticals, Inc.

INDUSTRY

NCT04826159 - IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2) | Biotech Hunter | Biotech Hunter